menu
    • menu
    [{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Inapplicable"}]

    Find Dermatology Clinical Drug Pipeline Developments & Deals by Celldex Therapeutics

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Celldex Therapeutics

                            U.S.A arrow
                            DIA 2025
                            Not Confirmed

                            Celldex Therapeutics

                            U.S.A arrow
                            DIA 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Barzolvolimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

                            Details : CDX-0159 (barzolvolimab) is a KIT inhibitor humanized monoclonal antibody. It is being evaluated for the treatment of patients with atopic dermatitis.

                            Product Name : CDX-0159

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            December 19, 2024

                            Lead Product(s) : Barzolvolimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Celldex Therapeutics

                            U.S.A arrow
                            DIA 2025
                            Not Confirmed

                            Celldex Therapeutics

                            U.S.A arrow
                            DIA 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Barzolvolimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Celldex Barzolvolimab Meets Endpoints in Phase 2 Urticaria Study

                            Details : CDX-0159 (barzolvolimab) is a KIT inhibitor humanized monoclonal antibody. It is being evaluated for the treatment of patients with chronic inducible urticaria.

                            Product Name : CDX-0159

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            October 26, 2024

                            Lead Product(s) : Barzolvolimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Celldex Therapeutics

                            U.S.A arrow
                            DIA 2025
                            Not Confirmed

                            Celldex Therapeutics

                            U.S.A arrow
                            DIA 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Barzolvolimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Celldex Reports Positive Results from Barzolvolimab Phase 2 Study in Urticaria

                            Details : CDX-0159 (barzolvolimab) is a KIT inhibitor humanized monoclonal antibody. It is being evaluated for the treatment of patients with chronic inducible urticaria.

                            Product Name : CDX-0159

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            July 29, 2024

                            Lead Product(s) : Barzolvolimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Celldex Therapeutics

                            U.S.A arrow
                            DIA 2025
                            Not Confirmed

                            Celldex Therapeutics

                            U.S.A arrow
                            DIA 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Barzolvolimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Celldex Announces First Patient Dosed in Ph 2 Study of Barzolvolimab in Prurigo Nodularis

                            Details : CDX-0159 (barzolvolimab) is an antibody that specifically binds the receptor tyrosine kinase KIT. It is being evaluated for the treatment of prurigo nodularis.

                            Product Name : CDX-0159

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 15, 2024

                            Lead Product(s) : Barzolvolimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Celldex Therapeutics

                            U.S.A arrow
                            DIA 2025
                            Not Confirmed

                            Celldex Therapeutics

                            U.S.A arrow
                            DIA 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Barzolvolimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Celldex Completes Enrollment in Phase 2 Study Of Barzolvolimab

                            Details : CDX-0159 (barzolvolimab) is a humanized monoclonal antibody targeting receptor tyrosine kinase KIT. It’s being evaluated for chronic inducible urticaria and symptomatic dermographism.

                            Product Name : CDX-0159

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 17, 2024

                            Lead Product(s) : Barzolvolimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Celldex Therapeutics

                            U.S.A arrow
                            DIA 2025
                            Not Confirmed

                            Celldex Therapeutics

                            U.S.A arrow
                            DIA 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Barzolvolimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Jefferies

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Celldex Therapeutics Announces Proposed Public Offering of Common Stock

                            Details : The proceeds will continue development of Celldex's product, including current and future development of CDX-0159 (barzolvolimab), growing its bispecific antibody platform and clinical candidates, funding ongoing efforts to develop additional clinical pi...

                            Product Name : CDX-0159

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            July 11, 2023

                            Lead Product(s) : Barzolvolimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Jefferies

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Celldex Therapeutics

                            U.S.A arrow
                            DIA 2025
                            Not Confirmed

                            Celldex Therapeutics

                            U.S.A arrow
                            DIA 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Barzolvolimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Jefferies

                            Deal Size : $200.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Celldex Therapeutics Announces Pricing of Public Offering of Common Stock

                            Details : The proceeds will continue development of Celldex's product, including current and future development of CDX-0159 (barzolvolimab), growing its bispecific antibody platform and clinical candidates, funding ongoing efforts to develop additional clinical pi...

                            Product Name : CDX-0159

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            July 11, 2023

                            Lead Product(s) : Barzolvolimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Jefferies

                            Deal Size : $200.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Celldex Therapeutics

                            U.S.A arrow
                            DIA 2025
                            Not Confirmed

                            Celldex Therapeutics

                            U.S.A arrow
                            DIA 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Barzolvolimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous ...

                            Details : CDX-0159 (barzolvolimab) is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT signaling controls the differentiation, tissue recruitment, survival and ac...

                            Product Name : CDX-0159

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 02, 2023

                            Lead Product(s) : Barzolvolimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Celldex Therapeutics

                            U.S.A arrow
                            DIA 2025
                            Not Confirmed

                            Celldex Therapeutics

                            U.S.A arrow
                            DIA 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Barzolvolimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria a...

                            Details : CDX-0159 (barzolvolimab) is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity.

                            Product Name : CDX-0159

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            June 12, 2022

                            Lead Product(s) : Barzolvolimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth